ライフサイエンスコーパス: mitral valve

1 s on the basis of valve position (aortic vs. mitral valve).

2 on both the fluid and solid mechanics of the mitral valve.

3 cluding the blood pool, pulmonary veins, and mitral valve.

4 ct through rotating reversal flow around the mitral valve.

5 phied septum and the anterior leaflet of the mitral valve.

6 f a single clip at the A2-P2 segments of the mitral valve.

7 with atrial fibrillation and a bioprosthetic mitral valve.

8 he effective regurgitant orifice area of the mitral valve.

9 in 11 myxomatous and 11 nonmyxomatous human mitral valves.

10 2 atrioventricular valves, 286 had a single mitral valve, 130 had a common atrioventricular valve, a

11 Mitral valve abnormalities were not part of modern patho

12 endpoint was technical success as defined by Mitral Valve Academic Research Consortium (MVARC) criter

13 ical endpoints are reported according to the Mitral Valve Academic Research Consortium (MVARC) defini

14 itral ViV and ViR were compared according to Mitral Valve Academic Research Consortium criteria.

15 success 30 days after implantation using the Mitral Valve Academic Research Consortium definitions.

16 The Mitral Valve Academic Research Consortium is a collabora

17 The rates of Mitral Valve Academic Research Consortium-defined device

18 the hypothesis that ischemic milieu modifies mitral valve adaptation.

19 This review will provide an overview of mitral valve anatomy, an update on the current transcath

20 ermore, LP therapy seems to adversely impact mitral valve and biventricular function.

21 rious positional placements of the MC in the mitral valve and its impact on reducing MR.

22 t of cardiac development but, along with the mitral valve and trabeculae, their developmental traject

23 at are attached to specified leaflets of the mitral valve and, subsequently, MC implants are placed i

24 ng are well-known causes of tricuspid valve, mitral valve, and cardiac dysfunction.

25 as discordant for seven pulmonary valves, 22 mitral valves, and 21 tricuspid valves.

26 primary morphofunctional abnormality of the mitral valve annulus.

27 re selected for score development, including mitral valve anterior leaflet thickening, excessive leaf

28 adults with isolated severe calcific MS and mitral valve area <=1.5 cm(2) from July 2003 to December

29 Mitral valve area and transmitral gradient (TMG) were 1.

30 that experimental tethering alone increases mitral valve area in association with endothelial-to-mes

31 Detailed mitral valve assessment is likely to assume increasing i

32 in the 1990s structural abnormalities of the mitral valve became appreciated as contributing to SAM p

33 ds, and outcomes of transcatheter aortic and mitral valve catheter-based valve procedures in the Unit

34 othesized that percutaneous plication of the mitral valve could reduce left ventricular outflow tract

35 ventricular damage (Stage 1), left atrial or mitral valve damage (Stage 2), pulmonary vasculature or

36 cardiac development as common mechanisms to mitral valve degeneration.

37 Mean mitral valve diameter z score was lower (P<0.001) and th

38 with increased repair rates of degenerative mitral valve disease (adjusted odds ratio [OR]: 1.13 for

39 ssisted examination for diagnosing aortic or mitral valve disease (of at least moderate severity) wer

40 ation (SMR) occurs in the absence of organic mitral valve disease and may develop as the left ventric

41 The field of mitral valve disease diagnosis and management is rapidly

42 ial tissues from the patients with rheumatic mitral valve disease in either sinus rhythm or persisten

43 ons from patients aged over 70 years who had mitral valve disease or atrial fibrillation when compare

44 ower the incidence of clinically significant mitral valve disease requires further study.

45 creased incidence of cardiovascular disease, mitral valve disease, arrhythmias, and mortality.

46 predispositions for certain diseases (i.e., mitral valve disease, atrial fibrillation and osteosarco

47 bserved the expected breed associations with mitral valve disease, atrial fibrillation, and osteosarc

48 t outcomes in patients with heart failure or mitral valve disease, but their impact on outcomes in pa

49 omen) consecutive patients with degenerative mitral valve disease, in whom LAVI was prospectively mea

50 ventricular systolic dysfunction, aortic or mitral valve disease, or pericardial effusion; and used

51 AC, a risk factor for clinically significant mitral valve disease, suggesting a causal association.

52 o promote the development of AF in rheumatic mitral valve disease.

53 prove outcomes in patients with degenerative mitral valve disease.

54 sural prolapse, as well as a mixed cause for mitral valve disease.

55 trial fibrillation or flutter or significant mitral valve disease.

56 g left ventricular dysfunction and aortic or mitral valve disease; FoCUS-assisted examination may hel

57 ten localized (for example, to the aortic or mitral valve), disease manifestations are regularly obse

58 Mitral valve diseases affect ~3% of the population and a

59 sociation between KCN and allergic rhinitis, mitral valve disorder, aortic aneurysm, or depression (P

60 ineae are selected to study their effects on mitral valve dynamics with fluid-structure interaction.

61 that different constitutive laws can affect mitral valve dynamics, such as the transvalvular flow ra

62 is associated with cardiovascular events and mitral valve dysfunction.

63 ound in patients suffering from nonsyndromic mitral valve dysplasia (MVD).

64 gical reoperation in patients with recurrent mitral valve failure after previous surgical valve repai

65 ase category, younger age, and morphological mitral valve features were risk factors for an unfavorab

66 bryos had increased crypt presence, abnormal mitral valve formation and alterations in the compaction

67 important interplay between LV geometry and mitral valve function in determining the clinical presen

68 remodeling and more effectively restored the mitral valve geometric configuration in ischemic MR, whi

69 power to detect a 5-mm Hg difference in mean mitral valve gradient at peak exercise, assuming an SD o

70 At 30-day follow-up, median mean mitral valve gradient was 7 mm Hg, most patients (96.7%)

71 Mean mitral valve gradients were similar between groups (6.4

72 CT assessment of the mitral valve has developed with equal rapidity, with reg

73 nts and mechanical properties for aortic and mitral valves have been studied, very little is known ab

74 Transcatheter mitral valve implantation (TMVI) is emerging as an alter

75 cally appropriate to determine transcatheter mitral valve implantation size and eligibility.

76 f the D-shaped MA to determine transcatheter mitral valve implantation size.

77 rgitation being considered for transcatheter mitral valve implantation who had undergone cardiac CT a

78 tflow Tract Obstruction During Transcatheter Mitral Valve Implantation; NCT03015194).

79 lei of endothelial and interstitial cells of mitral valves in mouse.

80 e of mechanical prosthetic and bioprosthetic mitral valves in patients aged 50 to 69 years matched by

81 ve analysis of mitral valve-in-valve (MViV), mitral valve-in-ring (MViR), and valve-in-mitral annular

82 ents who underwent mitral valve-in-valve and mitral valve-in-ring procedures were high risk, with an

83 A comprehensive analysis of mitral valve-in-valve (MViV), mitral valve-in-ring (MViR

84 Mitral valve-in-valve (ViV) and valve-in-ring (ViR) are

85 The 349 patients who underwent mitral valve-in-valve and mitral valve-in-ring procedure

86 ns have now been established as the cause of mitral valve insufficiency, and four different missense

87 s been an increase in focus on transcatheter mitral valve interventions, for both mitral repair and r

88 The mitral valve is a complex structure with a three-dimensi

89 The mitral valve is often structurally abnormal in hypertrop

90 ing prostheses specifically designed for the mitral valve is warranted.

91 d during follow-up in participants with T2D (mitral valve lateral E/Em increased 0.72+/-0.12 in women

92 ickness, morphology, left atrial volume, and mitral valve leaflet lengths (all P=non-significant).

93 Each underwent percutaneous mitral valve leaflet plication to reduce systolic anteri

94 Intentional laceration of the anterior mitral valve leaflet to prevent LVOT obstruction (LAMPOO

95 interventions that are directed only at the mitral valve leaflets (eg, transcatheter mitral valve re

96 , as well as structurally abnormal elongated mitral valve leaflets and remodeled intramural coronary

97 oint of a line connecting the origins of the mitral valve leaflets at end systole and end diastole.

98 rably to treatments that are directed to the mitral valve leaflets or their supporting structures (eg

99 eart valve form an ensemble, with the native mitral valve leaflets secured in between, thereby abolis

100 ium, biatrial enlargement, thickening of the mitral valve leaflets, and interatrial septum and mild p

101 ause annular dilatation and tethering of the mitral valve leaflets, there is a linear relationship be

102 willingness to accept risks associated with mitral valve medical devices.

103 omyopathy (HCM) and mild septal hypertrophy, mitral valve (MV) abnormalities may play an important ro

104 Concerning mitral valve (MV) annular geometry, we found significant

105 A paucity of data exists on mitral valve (MV) deformation during the cardiac cycle i

106 Degenerative mitral valve (MV) disease is a common cause of severe mi

107 ever, LV size is an important determinant of mitral valve (MV) leaflet tethering before and after rep

108 Conventional mitral valve (MV) operations allow direct anatomic asses

109 Mitral valve (MV) repair has become the standard therapy

110 Mitral valve (MV) repair is preferred over replacement i

111 ical outcomes and durability of percutaneous mitral valve (MV) repair with the MitraClip device compa

112 Transcatheter mitral valve (MV) repair with the MitraClip received app

113 Incidence and outcome of mitral valve (MV) surgery are unknown in patients with h

114 At 7.1 +/- 2.0 years, 86% had mitral valve (MV) surgery.

115 ume with hospital performance for aortic and mitral valve (MV) surgical procedures.

116 h suspected at least moderate MS ([1] native mitral valve [MV]: resting mean MV gradient >=5 mm Hg or

117 Mitral valves (MVs) are larger in such patients but fibr

118 oglycan expression was slightly lower in the mitral valves of MVP patients treated with MRA.

119 ence between peak twisting and untwisting at mitral valve opening (%untwMVO) using speckle-tracking e

120 th degenerative mitral disease who underwent mitral valve operations between 2002 and 2013.

121 Stage 1 (left ventricular damage), Stage 2 (mitral valve or left atrial damage), Stage 3 (tricuspid

122 Percutaneous closure of prosthetic mitral valve paravalvular leak (PVL) has emerged as an a

123 Precise definition of the mitral valve plane (VP) during segmentation of the left

124 This is a report of percutaneous mitral valve plication as a primary therapy in the manag

125 the potential effectiveness of percutaneous mitral valve plication as a therapy for patients with sy

126 nitial experience suggests that percutaneous mitral valve plication may be effective for symptom reli

127 Mean gradient across the mitral valve postprocedure was 5.7+/-2.8 mm Hg (>=5 mm H

128 prevalence of echocardiographically defined mitral valve prolapse (MVP) in the general population, t

129 Knowledge of mitral valve prolapse (MVP) inheritance is based on pedi

130 Background Mitral valve prolapse (MVP) is a common heart valve dise

131 Although the vast majority of mitral valve prolapse (MVP) is benign, a small subset of

132 Arrhythmic mitral valve prolapse (MVP) is characterized by myxomato

133 Mitral valve prolapse (MVP) is often considered benign b

134 Mitral valve prolapse (MVP) is one of the most common va

135 Longitudinal studies of mitral valve prolapse (MVP) progression among unselected

136 ipotent stem cells recapitulates features of mitral valve prolapse and identified dysregulation of th

137 Though most mitral valve prolapse are asymptomatic those that cause

138 Mitral valve prolapse is a common valvular abnormality b

139 disease valves will help relieve symptomatic mitral valve prolapse patients.

140 Mitral valve prolapse was present in 5.4%, Marfan syndro

141 trophic cardiomyopathy, cardiac amyloid, and mitral valve prolapse).

142 07-0.23), 0.12 (95% CI, 0.04-0.20) excluding mitral valve prolapse, and 0.44 (95% CI, 0.15-0.73) for

143 higher rates of scoliosis, pectus excavatum, mitral valve prolapse, and mutations in the CFTR gene.

144 es mellitus (DM), asthma, allergic rhinitis, mitral valve prolapse, collagen vascular disease, aortic

145 primary mitral regurgitation (MR) caused by mitral valve prolapse.

146 levance when referring patients with complex mitral valve prolapse.

147 athy, 0.86 for cardiac amyloid, and 0.77 for mitral valve prolapse.

148 er, transapical delivery of a self-expanding mitral valve prosthesis and were examined in a prospecti

149 MA was developed using Philips Q-Laboratory mitral valve quantification software.

150 n of TMVR in lower-risk patients with severe mitral valve regurgitation (Evaluation of the Safety and

151 F) and from 39 patients in sinus rhythm with mitral valve regurgitation (group 2; 32 males; 59+/-12 y

152 Secondary mitral valve regurgitation (MR) remains a challenging pr

153 s to the development of clinically important mitral valve regurgitation and mitral valve stenosis.

154 An increase in mitral valve regurgitation was observed in 38% of patien

155 istics, procedural characteristics (residual mitral valve regurgitation, periprocedural bleeding), si

156 epair (TMVr) with MitraClip in patients with mitral valve regurgitation.

157 Mitral valve reinterventions were identified through cla

158 with atrial fibrillation and a bioprosthetic mitral valve remain uncertain.

159 ng transition essential for proper embryonic mitral valve remodeling.

160 >65 years of age who underwent transcatheter mitral valve repair (MitraClip) for severe mitral regurg

161 placement (MVR), 10.5% (n = 8,219) underwent mitral valve repair (MVr), 5.4% (n = 4,202) underwent AV

162 the understanding of changes occurring after mitral valve repair (MVR).

163 Transcatheter mitral valve repair (TMVr) for the treatment of mitral r

164 tension influences outcomes of transcatheter mitral valve repair (TMVr) in patients with HF with SMR.

165 l Mitral Regurgitation) trial, transcatheter mitral valve repair (TMVr) led to reduced heart failure

166 e devices currently available, transcatheter mitral valve repair (TMVr) remains challenging in comple

167 itation, patients treated with transcatheter mitral valve repair (TMVr) through leaflet approximation

168 dary mitral regurgitation with transcatheter mitral valve repair (TMVr) using the MitraClip plus guid

169 rated health status benefit of transcatheter mitral valve repair (TMVr) with MitraClip in patients wi

170 l Mitral Regurgitation) trial, transcatheter mitral valve repair (TMVr) with the MitraClip rapidly im

171 demonstrated that edge-to-edge transcatheter mitral valve repair (TMVr) with the MitraClip resulted i

172 al regurgitation (MR) following degenerative mitral valve repair are poorly understood.

173 to evaluate renal function before and after mitral valve repair by the MitraClip device.

174 dge-to-edge technique using the percutaneous mitral valve repair device in an ex vivo pulsatile model

175 commercially treated with this percutaneous mitral valve repair device were analyzed.

176 etween 1991 and 2010, patients who underwent mitral valve repair for primary mitral regurgitation wer

177 After mitral valve repair for primary mitral regurgitation, th

178 the commercial experience with transcatheter mitral valve repair for the treatment of mitral regurgit

179 e-sixth of patients undergoing transcatheter mitral valve repair had AKI, linked to device failure or

180 predict postoperative LVD and outcome after mitral valve repair in patients with primary mitral regu

181 interventricular dyssynchrony, transcatheter mitral valve repair in patients with severe secondary mi

182 In addition, transcatheter mitral valve repair is also routinely used in high surgi

183 ted that recurrent MR following degenerative mitral valve repair is associated with adverse left vent

184 gs demonstrate that commercial transcatheter mitral valve repair is being performed in the United Sta

185 Guideline-directed medical therapy, surgical mitral valve repair or replacement, and, in the setting

186 uence of surgeon case volume on degenerative mitral valve repair rates and outcomes.

187 nnual mitral volumes of >50 and degenerative mitral valve repair rates of >70%, compared with surgeon

188 Degenerative mitral valve repair rates remain highly variable, despit

189 itral regurgitation (MR) were treated with a mitral valve repair system (MVRS) via small left thoraco

190 me in which patients underwent transcatheter mitral valve repair using the Edwards PASCAL TMVr system

191 fit-risk tradeoffs relevant to transcatheter mitral valve repair versus medical therapy for patients

192 cic Surgeons predicted risk of mortality for mitral valve repair was 4.8% (2.1-9.0) and 6.8% (2.9-10.

193 ents commercially treated with transcatheter mitral valve repair were analyzed.

194 Transcatheter mitral valve repair with a MitraClip device is also prod

195 Transcatheter mitral valve repair with the MitraClip in patients with

196 Transcatheter mitral valve repair with the MitraClip results in marked

197 eld has resulted in approval of edge-to-edge mitral valve repair with the MitraClip, and there are se

198 tery bypass graft, aortic valve replacement, mitral valve repair) using an interrupted time series mo

199 , cardiac resynchronization or transcatheter mitral valve repair), but they may derive little benefit

200 st- atrial fibrillation ablation or surgical mitral valve repair).

201 the mitral valve leaflets (eg, transcatheter mitral valve repair).

202 T2 inhibitors, vericiguat, and transcatheter mitral valve repair, all of which incrementally improve

203 ring transapical neochordae implantation for mitral valve repair, increasing accuracy and reproducibi

204 Transcatheter mitral valve repair, particularly edge-to-edge leaflet r

205 height >/=5 mm) and 5 others (8%) underwent mitral valve repair.

206 orable clinical response after transcatheter mitral valve repair.

207 ts who are being evaluated for transcatheter mitral valve repair.

208 l per square meter of body-surface area with mitral-valve repair and 60.6+/-39.0 ml per square meter

209 gurgitation undergoing CABG, the addition of mitral-valve repair did not lead to significant differen

210 bypass grafting (CABG) alone with CABG plus mitral-valve repair in patients with moderate ischemic m

211 In patients undergoing mitral-valve repair or replacement for severe ischemic m

212 We randomly assigned 251 patients to mitral-valve repair or replacement.

213 Mitral-valve repair provided a more durable correction o

214 Concomitant mitral-valve repair was associated with a reduced preval

215 In a randomized trial comparing mitral-valve repair with mitral-valve replacement in pat

216 lacement (AVR), 18.9% (n = 14,686) underwent mitral valve replacement (MVR), 10.5% (n = 8,219) underw

217 Limited data exist regarding transcatheter mitral valve replacement (TMVR) for patients with failed

218 More recently, transcatheter mitral valve replacement (TMVR) has emerged as a potenti

219 Transcatheter mitral valve replacement (TMVR) is a potential therapy f

220 Transcatheter mitral valve replacement (TMVR) is a rapidly evolving th

221 Transcatheter mitral valve replacement (TMVR) may be an option for sel

222 of a percutaneous transseptal transcatheter mitral valve replacement (TMVR) system.

223 f mortality and exclusion from transcatheter mitral valve replacement (TMVR).

224 replacement (TMVR) for patients with failed mitral valve replacement and repair.

225 Delaying definitive mechanical mitral valve replacement and the constraints of anticoag

226 h, and 3 patients required elective surgical mitral valve replacement at 6- to 54-month follow-up.

227 mong patients aged 50 to 69 years undergoing mitral valve replacement in New York State, there was no

228 to evaluate the potential for transcatheter mitral valve replacement in patients with severe MAC usi

229 I) is emerging as an alternative to surgical mitral valve replacement in selected high-risk patients.

230 Transcatheter mitral valve replacement in severe mitral annular calcif

231 Transcatheter mitral valve replacement is a novel therapeutic approach

232 cedures were high risk, with an STS PROM for mitral valve replacement of 11%.

233 , 0.90 (0.86-0.93) compared to dysfunctional mitral valve replacement or repair, 0.78 (0.70-0.90), P

234 t, 0.78 (0.73-0.87), P < .001, as did normal mitral valve replacement or repair, 0.90 (0.86-0.93) com

235 85 (74-96) seconds compared to dysfunctional mitral valve replacement or repair, 143 (128-192) second

236 ement, 36 patients with normally functioning mitral valve replacement or repair, 19 patients with dys

237 , P < .001, and also in normally functioning mitral valve replacement or repair, 85 (74-96) seconds c

238 nt or repair, 19 patients with dysfunctional mitral valve replacement or repair, and 31 patients with

239 ormance of a novel transseptal transcatheter mitral valve replacement system (Cephea Valve Technologi

240 sseptal delivery of the Cephea transcatheter mitral valve replacement system in an experimental model

241 ormance of the Twelve Intrepid Transcatheter Mitral Valve Replacement System in High Risk Patients wi

242 ON) is an effective adjunct to transcatheter mitral valve replacement that prevents left ventricular

243 Mean time from mitral valve replacement to percutaneous PVL repair was

244 Transcatheter mitral valve replacement using aortic transcatheter hear

245 for elective isolated or combined aortic and mitral valve replacement were included.

246 edure times (from traversal to transcatheter mitral valve replacement) were shorter, compared with th

247 oup at high or extreme risk for conventional mitral valve replacement.

248 re both independently associated with repeat mitral valve replacement.

249 r was 4.8% (2.1-9.0) and 6.8% (2.9-10.1) for mitral valve replacement.

250 ally in the forthcoming era of transcatheter mitral valve replacement.

251 rwent mechanical prosthetic vs bioprosthetic mitral valve replacement.

252 te the anterior leaflet before transcatheter mitral valve replacement.

253 tract obstruction required elective surgical mitral valve replacement.

254 air and 60.6+/-39.0 ml per square meter with mitral-valve replacement (mean changes from baseline, -9

255 il 70 years of age among patients undergoing mitral-valve replacement and until 55 years of age among

256 zed trial comparing mitral-valve repair with mitral-valve replacement in patients with severe ischemi

257 nderwent primary aortic-valve replacement or mitral-valve replacement with a mechanical or biologic p

258 In patients undergoing aortic-valve or mitral-valve replacement, either a mechanical or biologi

259 increased substantially for aortic-valve and mitral-valve replacement, from 11.5% to 51.6% for aortic

260 Among patients who underwent mitral-valve replacement, receipt of a biologic prosthes

261 alve replacement and from 16.8% to 53.7% for mitral-valve replacement.

262 e replacements and in 14 of 19 dysfunctional mitral valve replacements or repairs (P < .001 for both)

263 tic valve replacements and in 2 of 36 normal mitral valve replacements or repairs but were abnormal i

264 e implantation (eg, transcatheter aortic and mitral valve replacements) was further elucidated in lar

265 with atrial fibrillation and a bioprosthetic mitral valve, rivaroxaban was noninferior to warfarin wi

266 rial fibrillation without moderate or severe mitral valve stenosis or prosthetic mechanical heart val

267 lly important mitral valve regurgitation and mitral valve stenosis.

268 Diastolic mitral valve surface area was quantified by 3-dimensiona

269 ation with the development of indication for mitral valve surgery (0.83).

270 west after coronary artery bypass grafting + mitral valve surgery (1.38; 95% CI, 1.11-1.70).

271 ventricular ejection fraction, who underwent mitral valve surgery (92% repair) at our center between

272 re associated with higher mortality, whereas mitral valve surgery (HR: 0.82) was associated with impr

273 maker (PPM) implantation is higher following mitral valve surgery (MVS) with ablation for atrial fibr

274 mitral regurgitation in the 24 hours before mitral valve surgery and 13 age- and sex-matched healthy

275 alysis in patients with severe CPMR awaiting mitral valve surgery and stratified the study population

276 All patients who underwent open aortic or mitral valve surgery between January 1996 and December 2

277 c efficacy of targeted catheter ablation and mitral valve surgery in reducing the risk of life-threat

278 Mitral valve surgery is also challenging in these patien

279 The decision to undergo mitral valve surgery is often made on the basis of echoc

280 Prophylactic aortic root replacement and mitral valve surgery were rare during childhood versus a

281 Perioperative bleeding, aortic and mitral valve surgery, and septal surgery increased the o

282 ventricular ejection fraction who underwent mitral valve surgery, brain natriuretic peptide and LV-G

283 y artery bypass graft, aortic valve surgery, mitral valve surgery, or combined procedures.

284 ricular (LV) ejection fraction who underwent mitral valve surgery, we sought to discover whether base

285 ents with severe MR who are at high risk for mitral valve surgery.

286 41%) either died or developed indication for mitral valve surgery.

287 arranting close follow-up and perhaps, early mitral valve surgery.

288 artile range: 1 to 15 months), 65% underwent mitral valve surgery.

289 urgitation and is the leading indication for mitral valve surgery.

290 Patients With Atrial Fibrillation Undergoing Mitral Valve Surgery; NCT00903370).

291 (Early Feasibility Study of the Tendyne Mitral Valve System [Global Feasibility Study]; NCT02321

292 ed for morphofunctional abnormalities of the mitral valve that could explain a regional mechanical my

293 Following surgical repair of the mitral valve, the dyspnea and palpitations resolved.

294 Mitral valve thickening was observed in Fabry rats using

295 ramine administration, MRA treatment reduced mitral valve thickness and proteoglycan content.

296 tion by placement of MC in the center of the mitral valve to reduce MR.

297 though systolic anterior motion (SAM) of the mitral valve was discovered as the cause of LV outflow t

298 Subsequently, mitral valves were implanted in 10 pigs using a dedicate

299 Myxomatous mitral valve with prolapse are classically seen with abn

300 equent echocardiography revealing myxomatous mitral valve with prolapse.